⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30939643 | 1.00 | — | — | |
| SCHEMBL15011856 | 1.00 | — | — | |
| SCHEMBL9904899 | 0.90 | — | — | |
| SCHEMBL19846866 | 0.90 | — | — | |
| SCHEMBL17280422 | 0.89 | MMP13 (0.30) | — | |
| SCHEMBL30939606 | 0.89 | MMP13 (0.30) | — | |
| SCHEMBL9904821 | 0.89 | MMP13 (0.30) | — | |
| SCHEMBL9923877 | 0.86 | — | — | |
| SCHEMBL19670207 | 0.84 | — | — | |
| SCHEMBL21857962 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11197859-B2 | Hydantoin derivatives useful as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2021-12-14 | — | — | US | disclosed |
| US-20200360379-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | GLAXOSMITHKLINE S.P.A. (IT) | 2020-11-19 | — | — | US | disclosed |
| US-10555945-B2 | Compounds | AUTIFONY THERAPEUTICS LIMITED (GB) | 2020-02-11 | — | — | US | disclosed |
| US-20190000849-A1 | NOVEL COMPOUNDS | AUTIFONY THERAPEUTICS LIMITED | 2019-01-03 | — | — | US | disclosed |
| US-20180036308-A1 | NOVEL COMPOUNDS | AUTIFONY SRL (IT) | 2018-02-08 | — | — | US | disclosed |
| US-20180036308-A1 | NOVEL COMPOUNDS | AUTIFONY SRL (IT) | 2018-02-08 | — | — | US | disclosed |
| US-9833452-B2 | Compounds | AUTIFONY THERAPEUTICS LIMITED (GB) | 2017-12-05 | — | — | US | disclosed |
| US-9833452-B2 | Compounds | AUTIFONY THERAPEUTICS LIMITED (GB) | 2017-12-05 | — | — | US | disclosed |
| US-20160317537-A1 | NOVEL COMPOUNDS | AUTIFONY SRL (IT) | 2016-11-03 | — | — | US | disclosed |
| US-20160317537-A1 | NOVEL COMPOUNDS | AUTIFONY SRL (IT) | 2016-11-03 | — | — | US | disclosed |
| US-9422272-B2 | Compounds | AUTIFONY THERAPEUTICS LIMITED (GB) | 2016-08-23 | — | — | US | disclosed |
| US-9422272-B2 | Compounds | AUTIFONY THERAPEUTICS LIMITED (GB) | 2016-08-23 | — | — | US | disclosed |
| US-20150336936-A1 | NOVEL COMPOUNDS | AUTIFONY SRL (IT) | 2015-11-26 | — | — | US | disclosed |
| US-20150336936-A1 | NOVEL COMPOUNDS | AUTIFONY SRL (IT) | 2015-11-26 | — | — | US | disclosed |